Treatment of obesity with the pancreatic polypeptide analogue PP 1420

A single injection of a new drug, PP 1420, suppresses appetite for 24 hours in humans and is now being tested for its ability to reduce food intake and body weight. Obesity affects one in four UK adults and shortens life by driving heart disease, diabetes, and cancer. Existing treatments either work poorly or cause significant side effects. Pancreatic polypeptide (PP) is a natural hormone that powerfully curbs appetite, but it breaks down too quickly to be a practical drug. The researchers engineered a long-lasting version, PP 1420, delivered as a daily painless injection. A Phase 1a trial in humans showed it is safe and well tolerated, with effects lasting far longer than natural PP. If this Phase 1b and 1c trial succeeds, PP 1420 could become a new once-daily treatment for obesity that avoids the side effects of current drugs. That would directly help millions of people manage their weight and reduce their risk of chronic disease. The research is applied drug development, not fundamental science—the goal is a specific therapy, not a general discovery about biology.